FDA APPROVES IDARUCIZUMAB AS ANTIDOTE

The pharmaceutical journal group

首页> 外文期刊>The pharmaceutical journal >FDA APPROVES IDARUCIZUMAB AS ANTIDOTE

【24h】

FDA APPROVES IDARUCIZUMAB AS ANTIDOTE

机译：FDA批准IDARUCIZUMAB为抗病毒药

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The US medicines safety watchdog has given fast-track approval to idaruoizumab (Praxbind), a drug that can neutralise the effects of the anticoagulant dabigatran etexilate (Pradaxa).

机译：美国药品安全监督机构已对idaruoizumab（Praxbind）快速批准，该药可中和抗凝性达比加群酯（Pradaxa）的作用。

著录项

来源
《The pharmaceutical journal》 |2015年第7882期|共1页
作者
The pharmaceutical journal group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. FDA APPROVES IDARUCIZUMAB AS ANTIDOTE [J] . The pharmaceutical journal group The pharmaceutical journal . 2015,第7882期

机译：FDA批准IDARUCIZUMAB为抗病毒药
2. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval Supplemental Applications Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第6期

机译：当前与FDA有关的药物信息由FDA批准的新药，由FDA代理商批准的新剂型和适应症，待FDA批准的制造商提出的补充申请重大的标签变更或“与安全有关的亲爱的健康专业人士”
3. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第4期

机译：FDA批准的最新FDA相关药物信息新药FDA批准的新剂型和适应症FDA批准的FDA批准的重要标签变更或与安全相关的“亲爱的健康专业人员”字母
4. Using Machine Learning to Predict the Binding Dissociation of FDA Approved Drugs for Affinity- Based Drug Delivery Applications [C] . Edgardo Rivera-Delgado, Alison Xin, Horst A. von Recum Society for Biomaterials annual meeting and exposition . 2019

机译：使用机器学习预测基于亲和力的药物递送应用的FDA批准药物的结合解离
5. Molecular Determinants for Binding of the FDA-Approved Drugs in Proteins – A Data Mining and Advanced Quantum Chemical Study [D] . Alqahtani, Saad. 2017

机译：FDA批准的药物与蛋白质结合的分子决定因素–数据挖掘和先进的量子化学研究
6. First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab [O] . Steven Song, Joselle Cook, Clive Goulbourne, 2017

机译：新的解毒剂依达西珠单抗逆转达比加群使用相关的血红蛋白的首例报道
7. First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab [O] . Steven Song, Joselle Cook, Clive Goulbourne, 2017

机译：首次报告的血液术案与Dabigatran的使用逆转，新的解毒剂idarucizumab逆转

FDA APPROVES IDARUCIZUMAB AS ANTIDOTE

摘要

著录项

相似文献

相关主题

期刊订阅